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A sensitive ristocetin co-factor activity assay with 
recombinant glycoprotein Ibα for the diagnosis
of patients with low von Willebrand factor levels
Background and Objectives. The assay of ristocetin co-factor activity of von Willebrand
factor (VWF:RCo) is used in the screening of patients with suspected von Willebrand‘s dis-
ease (VWD), the most frequent inherited bleeding disorder. A correct diagnosis of VWD
relies on platelet agglutination tests that have a low accuracy within and between assays.
A more accurate VWF:RCo assay would improve VWD diagnosis and classification. 
Design and Methods. We describe here an ELISA method in which a recombinant frag-
ment of the α-subunit of platelet glycoprotein Ib-IX-V complex (rGPIbα) is bound to an
anti-GPIbα monoclonal antibody immobilized onto microtiter plate wells and which cap-
tures plasma VWF in the presence of ristocetin. The results obtained with this ELISA assay
were compared blindly with values calculated from the agglutination test in normal sub-
jects (n=60) and in patients with type 1 (n=8), type 2A (n=16), type 2B (n=13), type 2M
(n=17) or type 2M Vicenza (n=8) VWD characterized by low VWF levels.
Results. The two assays gave similar results in both normal subjects and VWD patients
(r=0.93), but the ELISA test had a higher sensitivity (0.1 versus 6.25 U/dL). The repeata-
bility and reproducibility of the ELISA had coefficients of variation of 9% and 10%, respec-
tively, as compared to 14% and 15% for the agglutination test. 
Interpretation and Conclusions. This ELISA assay can be useful in the identification and
classification of VWD patients in that it may provide a more accurate distinction between
type 2 disease with abnormal VWF function and type 1 disease with a low plasma con-
centration of VWF.
Key words: von Willebrand factor, von Willebrand’s disease, ristocetin co-factor
activity, von Willebrand factor activity, diagnosis and classification.
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Von Willebrand’s disease (VWD), themost frequent inherited bleeding dis-order, is caused by a deficiency and/or
abnormality of von Willebrand factor
(VWF).1,2 The revised classification of VWD
identifies two major categories, character-
ized by quantitative (types 1 and 3) or qual-
itative (type 2) VWF defects.3 Within the
first group, type 1 VWD is characterized by
a partial deficiency of VWF in plasma
and/orplateletswith concomitantly reduced
VWF activity and antigen but presence of
all the high molecular weight forms
observed in normal individuals, whereas in
type 3 VWD there is a total absence or only
trace amounts of VWF in plasma and
platelets.1-3 Type 2 VWD has been classified
into four distinct subtypes that reflect dif-
ferent pathophysiologic mechanisms.3 Type
2A VWD is characterized by the absence of
high molecular weight VWF multimers in
plasma and decreased efficiency of the
functions dependent on VWF binding to the
platelet glycoprotein (GP) Ib-IX-V complex.
Type 2B VWD is also characterized by a loss
of the largest plasma VWF multimers, but in
this case as a result of an increased affini-
ty for platelet GP Ib-IX-V complex. Type 2M
VWD exhibits decreased VWF-dependent
platelet functions in the presence of appar-
ently normal VWF multimers, suggesting
that is caused by mutations affecting VWF
activity but not its multimeric structure and
assembly.  Lastly, type 2N (Normandy) VWD
is characterized by a functional defect in
the N-terminal region of the molecule
where the binding site for coagulation fac-
tor VIII resides, with no change in the dis-
tribution of plasma VWF multimers.3
The ristocetin co-factor activity
(VWF:RCo) assay has been widely used in
the diagnosis of VWD because it reproduces
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in vitro the ability of VWF to interact with one of its
platelet receptor, the glycoprotein (GP) Ib-IX-V com-
plex.1,2 The original method for this assay was described
in 1974 by MacFarlane and is based on the property
of the antibiotic ristocetin to agglutinate formalin-
fixed normal platelets in the presence of VWF.4 As the
most common test of VWF activity, the VWF:RCo assay,
together with VWF:Ag, is traditionally considered the
first step in the diagnosis of VWD types.1,2 The use of
the VWF:RCo/Ag ratio has been recommended to dis-
criminate type 1 from type 2A, 2B and 2M VWD, as
reported in the guidelines for the diagnosis and treat-
ment of VWD in Italy. In fact, VWF:RCo values in
patients with type 1 VWD and normal subjects are
equivalent to those of VWF:Ag, and the resulting
VWF:RCo/Ag ratio is above the normal lower limit. In
contrast, levels of VWF:RCo lower than VWF:Ag, with
a VWF:RCo/Ag ratio below the normal lower limit, are
indicative of type 2A, 2B and 2M VWD.5
Since the original description, new ex vivo methods
have been proposed to measure VWF activity. Several
in house and commercial tests have been developed to
assay VWF:RCo, and attempts have also been made to
develop a ristocetin-independent ELISA6 but these
assays have not gained general acceptance.7 The avail-
ability of an ELISA assay for the collagen binding activ-
ity of VWF (VWF:CB), with a sensitivity as low as 0.1
U/dL, has prompted several laboratories to use this
method instead of the VWF:RCo assay, on the assump-
tion that both tests are sensitive to the presence of the
VWF multimers of largest size and can be used to dis-
criminate between patients with normal or abnormal
VWF multimeric structure.8,9 However, assaying
VWF:CB cannot in principle substitute for the meas-
urement of VWF:RCo because only the latter directly
reflects the interaction mediated by the platelet gly-
coprotein Ib-IX-V receptor that is essential for VWF
function in hemostasis and thrombosis.10,11
More recently, a reliable and reproducible ELISA
method to measure VWF:RCo using a recombinant
fragment of the α-subunit of the GP Ib (rGPIbα), the
VWF binding subunit of the GP Ib-IX-V complex, has
been developed, but this test has not yet been used
extensively in clinical practice and is not commercial-
ly available.12 Here we describe a similar ELISA method
in which plasma VWF binds to a different recombi-
nant fragment of the α-subunit of the GP Ib (rGPIbα).
Our results demonstrate that the sensitivity of this
assay exceeds that of any currently available method
for the measurement of VWF:RCo. The method can be
used to discriminate type 2 VWD from previously
defined type 1 VWD patients, especially when VWF:Ag
levels are low, and should facilitate the diagnosis, clas-
sification and management of VWD.
Design and Methods
Plasma from VWD patients and normal controls
Blood from 60 healthy volunteers and 62 patients
with VWD attending the Angelo Bianchi Bonomi
Hemophilia Thrombosis Center of Milan was drawn
into 1/10th volume of 3.13% sodium citrate. Patients
and normal individuals gave their informed consent
according to the rules of the local Institutional Review
Board. Platelet-poor plasma (PPP) was prepared by
centrifugation at 1,500 × g for 15 min. Plasma was
stored in small aliquots at –70° C prior to testing.  The
VWD patients were selected from among the 484 fol-
lowed at the Center according to their previous diag-
nosis of type 1 with low VWF:Ag levels (n=8), 2A
(n=16), 2B (n=13), 2M (n=17) or 2M ”Vicenza” (n=8)
VWD. Criteria for these diagnoses were derived from
the recommendations of the Scientific Standardiza-
tion Committee on VWF of the International Society of
Thrombosis and Haemostasis3 and they were translat-
ed into a diagnostic flow chart, as recently reported in
the guidelines for diagnosis and treatment of VWD in
Italy.5 In order to prove the potency of the assays to
measure VWF activity, we also selected 9 patients with
very low  (<15 U/dL) VWF:Ag levels and defined genet-
ic abnormalities (see below).
Assays for VWD diagnosis already in use:
VWF:Ag-ELISA
Microtiter plates (96 wells) were coated overnight at
4°C with 125 mL/well of polyclonal anti-VWF-anti-
body (Dako): 1 to 1000 in 50 mM carbonate buffer, pH
9.6. After washing four times with PBS-0.01% Tween
20, the plates were blocked for 1 hour at room tem-
perature (RT) with 250 mL/well of a 5% BSA-TBS solu-
tion.  After additional washing, standard plasma pool
dilutions (from 1:50 to 1:3200) and diluted test sam-
ples, all in 0.1% BSA-TBS solution, were added in
duplicate to the wells and incubated for 2 hours at RT.
The wells were then washed and a rabbit anti-human-
VWF antibody labeled with horse radish peroxidase
(HRP, 0.5 µg/mL in 0.1% BSA-TBS) was added and
incubated for 1 hour at RT (Dako, Glostrup, Denmark).
After a final washing, the bound antibody was quan-
tified with a colorimetric reaction by adding the HRP
substrate 1,2 ortho-phenylendiamine dihydrochloride
(OPD) at the concentration of 400 µg/mL. The reaction
was stopped with 4 mol/L H2S04 and the absorbance
read at 492 nm. VWF:Ag was calculated by extrapola-
tion from the log calibration curve. The sensitivity of
this in house VWF:Ag assay was 0.1 U/dL. The average
normal value of VWF:Ag obtained in 100 normal indi-
viduals with O and non-O blood groups is 112±36 U/dL,
with a range of 50-218 U/dL.
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VWF:RCo by agglutination
The in house assay for VWF:RCo determined by
platelet agglutination was derived from the original
one described by MacFarlane.  In this assay human
formalin-fixed platelets derived from blood bank
donors were used as a source of GPIbα. The test was
performed in a two-channel aggregometer connected
to a recorder (Chronolog). Fifty microliters of dilutions
of normal or patients’ plasma were added to 200 µL
of formalin-fixed platelets (250×109/L) prepared in a
siliconized glass tube containing a stirring bar. After
15-20 seconds used to calibrate the aggregometer and
to record the baseline curve, 5 µL of ristocetin solu-
tion  (1 mg/mL final concentration) were added into
the stirring cuvette, and the maximal agglutination
was determined.  A standard curve with 5 dilutions of
the normal plasma pool was created at the beginning
and at the end of the daily assay and at least three
dilutions of test plasma were used in duplicate to
measure VWF:RCo. The standard curve of the normal
pool was obtained by plotting, on a semilog scale, the
maximum rate of agglutination, measured from the
maximum slope of each agglutination trace, as a func-
tion of plasma dilution. The 1:2 dilution of the normal
pool was considered as 100 U/dL and significant agglu-
tination was usually seen with a 1:32 dilution, corre-
sponding to 6.25 U/dL. The average normal value of
VWF:RCo measured by agglutination obtained in 100
normal individuals with O and non-O blood groups
was 110±35 U/dL, with a range of 46-202 U/dL. The
VWF:RCo/Ag ratio in this control group was 0.99±0.23,
with a range of 0.63-1.75.
VWF:CB-ELISA
Microtiter plates (96 wells) were coated overnight at
RT with 110 µL/well of collagen solution (25 µg/mL;
95% type I and 5% type III) previously diluted in Horm
buffer (HORM-NYCOMED 7806141). After washing
four times with 0.02 M TBS-0.1% Tween, the wells
were blocked by over-coating with a 3% BSA-TBS
solution for 1 hour at RT. After additional washing,
100 µL/well of diluted plasma samples were added. At
least 7 normal pool dilutions (from 1:50 to 1:3200)
were used to prepare the standard curve and 3 test
sample dilutions were assayed.  After 2 hours of shak-
ing incubation at RT, the wells were washed and 100
mL of diluted HRP-conjugated anti-VWF antibody
were added to each well, as described for the VWF:Ag
ELISA. After an additional 1 hour incubation at RT, the
wells were washed and the bound antibody was quan-
tified with a colorimetric reaction, as described for the
VWF:Ag ELISA. VWF:CB was calculated by extrapola-
tion from a bi-log calibration curve. The sensitivity of
this in house VWF:CB assay was 0.1 U/dL. The average
value of VWF:CB obtained in 100 normal individuals
with O and non-O blood groups was 115±46 U/dL, with
a range of 50-194 U/dL. The VWF:CB/Ag ratio in this
control group was 1.03±0.26, with a range of 0.59-
1.87.
New VWF:RCo ELISA test: monoclonal
antibodies
The anti-GPIbα monoclonal antibody, LJ-P3, has
been previously described.13 This antibody recognizes a
conformation-specific epitope present in the amino
terminal domain of GPIbα (residues 1-290) and does
not inhibit VWF binding to GPIbα. The reactivity of LJ-
P3 with a recombinant fragment of GPIbα has been
previously described.14
Culture of insect cells expressing
recombinant GPIbαa
The amino terminal domain of GPIbα was produced
by stably transfected Drosophila melanogaster S2-cells
(Invitrogen, Carlsbad, CA, USA), as described else-
where.15 The fragment comprises residues 1-290 of the
mature protein and contains a mutation of the
unpaired Cys65 residue to Ala, introduced to prevent
the slow formation of dimers observed when the pro-
tein was kept in solution for prolonged periods. The
atomic structure of this recombinant fragment has
recently been determined by X-ray crystallography.15
For these studies, the culture medium of transfected
insect cells was used as the source of GPIbα fragment
(dilutions 1:10-1:100).
Method for the VWF:RCo ELISA test
The principles of the method are described in Figure
1. An anti-GPIbα monoclonal antibody (LJ-P3) was
bound to an ELISA plate to capture rGPIbα from the
culture medium of transfected insect cells. The rGPI-
bα fragment bound to LJ-P3, in turn, captured plasma
VWF in the presence of ristocetin; then, bound VWF
was detected by a polyclonal anti-VWF antibody con-
jugated with HRP. The VWF:RCo was derived from the
amount of VWF bound in the well and determined
through a colorimetric reaction.  In detail, microtiter
plates (96 wells) were coated overnight at 4°C with
100 µL of monoclonal antibody LJ-P3 (5 µg/mL in PBS).
After washing four times with PBS-0.01%-Tween 20,
100 µL of a solution containing 2-8 mg/L rGPIbα were
added. After overnight incubation at 4°C, the plates
were washed and blocked with 5% BSA (250 µL/well)
for 1 hour at RT. After additional washing, 50 µL of
standard plasma pool dilutions in PBS-0.1%-BSA-
0.01% Tween 20 (from 1:100 to 1:6400) and diluted
test samples were added to the wells. Plasma pool
dilutions were assayed in triplicate and test samples in
duplicate. At this point, 50 µL/well of 1.6 mg/mL ris-
tocetin solution (Sigma) in PBS were added, and the
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mixtures were incubated for 2 h at RT. Following this
step and after washing, a rabbit anti-human-VWF
antibody with conjugated HRP (Dako, Glostrup, Den-
mark) was added at a concentration of 0.5 mg/mL in
PBS-0.1%-BSA-0.01% Tween 20 and incubated for 1
hour at RT. After additional washing, the amount of
bound VWF was determined by a colorimetric reac-
tion as described for the assay of VWF:Ag by ELISA
(see above).
Validation of the VWF:RCo ELISA test in
comparison with VWF:RCo by agglutination
The VWF:RCo ELISA was compared with the in house
VWF:RCo performed by platelet agglutination (see
above). The repeatability of the two assays was deter-
mined by assaying 6 replicates of 5 dilutions of a nor-
mal plasma pool in one run, and the reproducibility by
assaying 6 replicates of the same plasma samples over
3 days, with the test performed by two technicians. The
sensitivity was expressed as the minimal value meas-
urable in the series of diluted standards.
Statistical analysis
Laboratory data were expressed as means with
ranges. The t-test was used to compare the results
obtained with the assay of VWF:RCo by agglutination
and ELISA; p values < 0.05 were accepted as statistially
significant. 
Results
Ristocetin-induced binding of plasma VWF
to rGPIbαa
The binding of plasma VWF to the captured rGPIbα
in the presence of various concentrations of ristocetin
was tested in the assay. An optimal binding curve was
obtained at a ristocetin concentration of 0.8 mg/mL
with no significant differences observed at 1 mg/mL
(Figure 2). Therefore, a standard concentration of 0.8
mg/mL was used to peform the VWF:RCo ELISA. The
specificity of the binding of VWF to rGPIbα in the pres-
ence of ristocetin was determined by using the medi-
um of non-transfected cells as a negative control (data
not shown).
Assessment of VWF:RCo by ELISA
The new ELISA method was evaluated in our labo-
ratory in a blind comparison with the previously avail-
able VWF:RCo assay. The VWF:RCo levels in a series of
dilutions (1:100 to 1:3200) of a plasma pool were
measured in the ELISA. By plotting optical density ver-
sus VWF:RCo activity we obtained a curve in a semi-
log scale (Figure 3). The repeatability of the VWF:RCo
assays by platelet agglutination and ELISA had a mean
coefficient of variation (CV) of 14% and 9%, respec-
tively; the reproducibility had a mean CV of 15% and
10%, respectively. In contrast, the sensitivity of ELISA
Figure 1. Schematic repre-
sentation of the VWF:RCo
assay by ELISA using rGPI-
bαa. An anti-GPIbαa mono-
clonal antibody (MoAb) is
bound to an ELISA plate
(A) and captures rGPIbαa
(residues His1-Arg290) pres-
ent in the culture medium
of transfected insect cells
(B). The rGPIbαa fragment
bound to LJ-P3, in turn,
captures plasma VWF in
the presence of ristocetin
(C) and the captured VWF
is detected by a polyclonal
anti-VWF antibody conju-
gated with horse radish
peroxidase (D). The
VWF:RCo is calculated by
measuring the OD at 492
nm.  
A B C D E
Add substrate
Read OD
492 nm
Diluted
Plasma 
+ 
RistocetinrGPIbαa
anti-GPIbαa
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Anti-VWF-HRP
Conjugated
Polyclonal
Antibody
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was much higher than that of the in house agglutina-
tion method: 0.1 versus 6.25 U/dL (Figure 3). 
Measurements of VWF:RCo in plasma from
normal individuals and from VWD patients
The mean values and ranges of VWF:RCo levels meas-
ured with the two assays in both normal individuals and
in different VWD patients are reported in Table 1 and a
comparison of the corresponding absolute values is pre-
sented as a scatter plot in Figure 4. In terms of absolute
levels of VWF:RCo, the two assays gave similar results
in both normal subjects and VWD patients (r=0.93). The
VWF:RCo/Ag ratios were also calculated using the val-
ues from both assays. When the VWF:RCo level meas-
ured by agglutination was < 6 U/dL, we used the arbi-
trary value of 5 U/dL to perform statistical analyses and
to calculate the VWF:RCo/Ag ratio. The ratios obtained
with the two VWF:RCo assays were not statistically dif-
ferent in normal individuals and in patients with types
2A, 2B and 2M VWD, the slight differences found being
probably related to the CVs of these assays. Only the two
groups of patients with type 2M Vicenza and those with
previously diagnosed type 1 platelet low VWD had sig-
nificantly different ratio values: 0.7 and 0.4 using the
Figure 2. Ristocetin-induced
binding of plasma VWF to
rGPIbαa. Binding of plasma
VWF (dilutions from 1:32 to
1:512) to rGPIbαa was stud-
ied in the presence of
increasing concentrations of
ristocetin: 0.5 mg/mL
(closed triangles), 0.6
mg/mL (open squares), 0.8
mg/mL (closed circles) and
1 mg/mL (open circles).
There was not a significant
difference between the
results for the 0.8 and 1
mg/mL final ristocetin con-
centrations.
Figure 3. Sensitivity of
the two VWF:RCo assays
as tested by standard
curves obtained with
decreasing dilutions of a
normal plasma pool. The
log of the VWF:RCo con-
centrations (U/dL) in the
plasma dilutions is shown
on the abscissa; the log
of the OD at 492 nm for
the ELISA (left) or the
maximum slope in the
agglutination curve, for
the platelet agglutination
test, is shown on the ordi-
nate. Note that the sen-
sitivity of the ELISA test
is greater than that of the
agglutination test.  
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results of the ELISA test, versus 1.4 and 0.7 using the
platelet agglutination assay (Table 1).
To explore further the potency of both VWF:RCo
assays in making a correct VWD diagnosis we selected
9 patients with VWF:Ag < 15 U/dL and known muta-
tions in the VWF gene. The data from all the available
assays performed in these VWD patients are summa-
rized in Table 2. Patients #1, 2, and 3 were originally
diagnosed as having type 1 platelet low VWD because
of low VWF levels in both plasma and platelets, a nor-
mal multimeric pattern of VWF, and reduced ristocetin-
induced platelet agglutination (RIPA). Testing VWF:RCo
by agglutination these patients exhibited VWF:RCo/Ag
ratios of 1.5, 1.00 and 0.75, respectively, consistent
with the corresponding VWF:CB/Ag ratios of 0.90, 0.83,
0.75, which suggested a diagnosis of type 1 VWD. Using
the more sensitive ELISA, the VWF:RCo/Ag ratios were
0.05, 0.06, 0.10 suggesting type 2 defects. All these
VWD patients had mutations in specific VWF exons
(Table 2).
Patients #4, 5, and 6 were members of three differ-
ent families with the well-characterized type 2M
Vicenza VWD showing supranormal multimers in their
plasma and the same VWF gene defect (R1205H of
the entire pre-pro-VWF subunit). Using the VWF:RCo
agglutination test, these patients had a VWF:RCo/Ag
ratio of 1.20, 1.00 and 0.83, respectively, consistent
with the VWF:CB/Ag ratios of 0.80, 1.16, 1.00, thus
suggesting a diagnosis of type 1 Vicenza. Using the
ELISA, the VWF:RCo/Ag ratios were 0.24, 0.58, 0.32
suggesting type 2M Vicenza defects of reduced VWF
(Table 2).
Patients #7, 8, and 9 were members of three differ-
ent families affected by type 2A and 2B VWD, with
well known mutations within exon 28. Patient #9 was
affected by type 2B VWD, as indicated by an enhanced
RIPA. In these cases the VWF:RCo/Ag ratios evaluated
by both VWF:RCo assays were always below the nor-
mal lower limit even though the values detected by
ELISA were lower (Table 2). The VWF:RCo/Ag ratios
were below the normal lower limit in both assays, in
agreement with the VWF:CB/Ag ratios of 0.4, 0.04,
0.01, respectively, and a loss of the large molecular
weight multimers, typical of type 2 VWD.
Table 1. Mean values (ranges) of  VWF:RCo levels in normal individuals and in patients with different types of VWD.
Individuals VWF:RCo (U/dL) VWF:RCo-(U/dL) VWF:RCo/Ag VWF:RCo/Ag
tested (n) Agglutination ELISA Agglutination ELISA
Normal  subjects 106 96 0.90 0.80
(n=60) (50-166) (46-168) (0.7-1.4) (0.7-1.2)
Type 1 low 15 12 1.4 0.7(*)
(n=8) (<6-37) (0.5-29) (0.7-2.5) (0.3-1.2)
Type 2A 9 9 0.3 0.2 
(n=16) (<6-36) (1-53) (0.1-0.4) (0.1-0.6) 
Type 2B 21 17 0.5 0.4
(n=13) (11-54) (4-44) (0.3-0.9) (0.1-0.8)
Type 2M 11 9 0.3 0.2
(n=17) <6-38) (4—37) (0.1-0.6) (0.1-0.6)
Type “Vicenza” < 6 3 0.7 0.4(*)
(n=8) (<6) (0.9-6) (0.5 -1.0) (0.2 - 0.7)
To calculate the mean values of VWF:RCo and the VWF:RCo/Ag ratios, VWF:RCo levels below the limit of sensitivity of the agglutination assay (<6  IU/dL) were arbitrarily
assigned the values of 5  U/dL  (*) p < 0.05.
Figure 4. Scatter plot analysis comparing the plasma val-
ues of VWF:RCo (U/dL) in normal individuals and patients
with VWD obtained with the agglutination (x axis) or the
ELISA (y axis) assays. There is a good correlation
between the two methods (r=0.93).
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F:
R
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Discussion
The high variability and low sensitivity of the com-
monly used assays for VWF:RCo, a key parameter for
the diagnosis of VWD, depend in part on differences in
equipment and the reagents used for the test. The use
of platelets and the inherent difficulty they pose as a
reliable and consistent source of GPIbα are foremost
in this problem.  
The development of an ELISA for VWF:RCo has sat-
isfactorily addressed both these issues and allowed the
measurement of VWF:RCo activity in plasma with the
same sensitivity as that provided by the VWF:Ag
ELISA.12 We have established an ELISA assay for
VWF:RCo based on the same principles described in a
previous publication12 but with a different recombi-
nant fragment of GPIbα and a different anti-GPIbα
antibody.13-15 We found that this VWF:RCo ELISA assay
provides results similar to those of the common
platelet agglutination test but with less variability and
greatly increased sensitivity. 
To determine the potency of this ELISA for VWF:RCo,
we applied the method specifically to VWD patients
with very low VWF:Ag and found that the greater sen-
Table 2. Summary of data obtained in VWD patients  (n=9)  with VWF:Ag < 15 U/dL.
Test used for #1 #2 #3 #4 #5 #6 #7 #8 #9
diagnosis (CL) (TS) (C.E) (NL) (CD) (MM) (BA) (PP) (FM)
(initials)
VWF:Ag (U/dL) 2 3 4 5 6 6 10 11 15
VWF: RCo(U/dL)
Agglutination < 6 < 6 < 6 6 6 5 6 < 6 10   
ELISA 0.1 0.2 0.4 1.2 3.5 1.9 3.9 2.2 6
VWF: CB (U/dL) 1.8 2.5 3 4 7 6 7 0.5 0.2      
VWF:RCo/Ag  (ratio)
Agglutination 1.5 1.00 0.75 1.20 1.00 0.83 0.60 0.54 0.66
ELISA 0.05 0.06 0.10 0.24 0.58 0.32 0.39 0.20 0.40
VWF: CB/Ag 0.90 0.83 0.75 0.80 1.16 1.00 0.4 0.04 0.01
(ratio)
Ristocetin Induced
Platelet Agglutination > 2.5 > 2.5 2.4 1.2 2.0 1.6 1.8 > 2.5 0.6
(RIPA) (mg/mL)
High molecular weight multimers  (low resolution gels):
present Yes Yes Yes Yes Yes Yes No No No
supranormal No No No Yes Yes Yes No No No
Platelet VWF Low Low Low Normal Normal Normal Normal Normal Normal
Mutation analysis:
Found Yes Yes Yes Yes Yes Yes Yes Yes Yes
Candidate mutations 
localized in VWF-exons 31/43 32 31/43 27 27 27 28 28 28           
Diagnosis of VWD type using VWF:RCo:
Agglutination 1 1 1 1Vic 1Vic 1Vic 2A 2A 2B
ELISA 2 2M 2M 2MVic 2MVic 2MVic 2A 2A 2B
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sitivity of the assay allowed a more accurate diagno-
sis and classification of VWD.
Different VWF:RCo/Ag ratios were obtained with the
two assays only in type 1 VWD with low VWF:Ag. In the
other VWD types this difference was not as evident
because VWF:Ag levels are usually >15 U/dL. The diag-
nosis with this ELISA was more accurate in VWD patients
with type 1 platelet low (3 cases), type Vicenza (3 cas-
es),  2A (2 cases) and 2B (1 case) VWD characterized by
VWF:Ag levels lower or equal to 15 U/dL. 
Three subgroups of type 1 VWD have been proposed in
the past, depending on the content of platelet VWF.16
The results obtained with the VWF:RCo ELISA test now
indicate that VWF is dysfunctional in the so-called
platelet low type 1 VWD, typically considered to have low
levels of normal VWF, and these patients may be more
properly considered as having type 2 VWD. In another
subtype, type Vicenza, the typical phenotype is charac-
terized by relatively low VWF levels and supranormal
multimers in plasma.17 Patients with Vicenza type VWD
show at least one specific mutation, R1205H, located in
exon 27 of the VWF gene.18 Discussion is still open about
whether these patients can be classified as having type
1 or 2 VWD.19 Based on our results in the affected mem-
bers of three different families, who have VWF:RCo/Ag
ratios below the normal lower limit, type 2 disease seems
the more appropriate diagnosis. In the case of type 2A
or 2B VWD, the diagnosis typically relies on the evidence
of a loss of the higher molecular weight multimers or an
abnormal response to ristocetin in platelet-rich plasma,
decreased in one case (type 2A) and enhanced at a low-
er concentration of ristocetin in the other (type 2B). Our
data illustrate that, in these patients, the VWF:RCo/Ag
ratios obtained by ELISA are much lower than those by
the platelet agglutination test, enhancing the ability to
detect the abnormal VWF.
This ELISA assay for VWF:RCo showed a sensitivity
similar to that of the VWF:CB. The two assays are dif-
ferent in that they are based on different VWF functions,
binding to collagen via the VWF A3 domain in one case
and binding to GPIbα via the A1 domain in the other.2
When VWF:CB is tested, it should be evaluated in com-
bination with VWF:RCo, because both assays can
improve the diagnosis of VWD subtypes, as previously
reported.11 In fact, specific VWF:CB defects have also
been identified in the presence of normal VWF:RCo in
some patients.20 The different roles of VWF:RCo and
VWF:CB in the diagnosis of VWD are also supported by
the discrepant results obtained by these two assays in
the small group of patients with low VWF:Ag selected
here to determine the potency of the ELISA for VWF:RCo.
In fact, the VWF:CB/Ag ratio was always above the nor-
mal limit but the VWF:RCo/Ag ratio was low in type 2M
and Vicenza VWD patients who are characterized by
having an apparently normal VWF multimeric structure.
Based on these and previous observations, we suggest
using both VWF:RCo and VWF:CB normalized with
VWF:Ag in the diagnosis of VWD types and then corre-
lating the results of these assays with the pattern derived
from the analysis of VWF multimers.11
An updated definition of type 2M VWD is still under
consideration by the Scientific Standardization Com-
mittee on VWF of the International Society of Thrombo-
sis and Haemostasis. Some authors have suggested that
patients with a low VWF:RCo/Ag ratio, decreased RIPA
and normal or near normal multimeric structure are car-
riers of qualitatively abnormal VWF and should be clas-
sified as having type 2M VWD.21 In our study we only
evaluated a few cases with known mutations in specif-
ic VWF exons, but this issue will be further explored in
the large, ongoing European study on molecular and
clinical markers for diagnosis and treatment of type 1
VWD.
Type 1 VWD, with a complete set of multimers similar
to that found in normal individuals, is characterized by
both VWF:RCo/Ag and VWF:CB/Ag ratios similar to those
in healthy subjects. Conversely, types 2A and 2B, with a
relative loss of high molecular weight multimers, always
show both VWF:RCo/Ag and VWF:CB/Ag ratios below
normal limits. Type 2M VWD patients apparently have a
full set of multimers but by definition their VWF is
abnormal in its interaction with platelet GPIbα, as a
result of specific mutations within the A1 domain. Thus,
the VWF:CB/Ag ratio is within the normal range but the
VWF:RCo/Ag is below the lower normal limit.11 In con-
clusion, our data demonstrate that our ELISA assay for
VWF:RCo using rGPIbα correlates well with an in house
agglutination method but offers the advantages of low-
er inter- and intra-assay variability (CV<10%) and, above
all, a much better sensitivity. Implementation of this
assay could improve the diagnosis of VWD patients by
providing a clearer distinction between type 2 (abnormal
VWF) and type 1 VWD, especially when VWF antigen
levels are low.
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